A Single-Center, Prospective Phase II Clinical Study of Proton Beam Intensity-Modulated Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer

Inclusion Criteria

• •1. .Lung cancer confirmed by histology and/or cytology; and in the absence of pathological diagnosis, patients who meet the following conditions can also be included: diagnosed by more than 2 imaging modalities, and the clinical diagnosis of lung cancer is confirmed after MDT discussion.
• •2. The clinical staging based on PET-CT examination is: cT1\~3 N0M0, stage IA-IIB (AJCC eighth edition).
• •3. Age: 18 years and above.
• •4. KPS score ≥60.
• •5. The doctor assesses that surgical treatment is not suitable or the patient refuses surgery.
• •6. Relatively good organ function:
• •7. Normal bone marrow function: WBC≥3×109/L, Platelet ≥80×109/L, HGB≥90g/L
• •8. Normal liver and kidney function:
• •9. Total bilirubin, AST, and ALT≤2.0×upper limit of normal values;
• •10. Creatinine clearance ≥60ml/min or creatinine ≤1.5×upper limit of normal value
• •11. The patient has signed an informed consent form and is willing and able to comply with planned study visits, treatment plans, laboratory tests, and other study procedures.